Education
About Us
Working with TipRanks
Follow Us
Biodesix (BDSX)
NASDAQ:BDSX
BDSX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.17 - $2.04
Previous CloseN/A
Volume171.18K
Average Volume (3M)1.34M
Market Cap
$68.18M
Enterprise Value$92.70M
Total Cash (Recent Filing)$20.73M
Total Debt (Recent Filing)$72.14M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Oct 31, 2025EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding146,633,350
10 Day Avg. Volume977,540
30 Day Avg. Volume1,340,692
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.36
Enterprise Value/Revenue1.21
Enterprise Value/Gross Profit1.54
Enterprise Value/Ebitda-3.13
Forecast
1Y Price Target
$1.75Price Target Upside272.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company reported 2Q25 results that were ahead of estimates and FactSet consensus, showing solid lung diagnostics test volume growth and revenue growth.
Sales StrategyBDSX's rapid near-term sales force expansion and updated primary care commercial focus could drive continued top-line growth.
Bears Say
Revenue GuidanceBiodesix decreased its 2025 revenue guidance to $80-85 million from $92-95 million, driven by relatively slower than anticipated expansion of the sales force.
Sales Force ChallengesThe company's 1Q25 performance was impacted by meaningful decreases to the sales force and slower than anticipated hiring of new primary care focused sales reps.
Biodesix News
BDSX FAQ
What was Biodesix’s price range in the past 12 months?
Biodesix lowest stock price was $0.17 and its highest was $2.04 in the past 12 months.
What is Biodesix’s market cap?
Biodesix’s market cap is $68.18M.
When is Biodesix’s upcoming earnings report date?
Biodesix’s upcoming earnings report date is Oct 31, 2025 which is in 63 days.
How were Biodesix’s earnings last quarter?
Biodesix released its earnings results on Aug 07, 2025. The company reported -$0.08 earnings per share for the quarter, missing the consensus estimate of -$0.069 by -$0.011.
Is Biodesix overvalued?
According to Wall Street analysts Biodesix’s price is currently Undervalued.
Does Biodesix pay dividends?
Biodesix does not currently pay dividends.
What is Biodesix’s EPS estimate?
Biodesix’s EPS estimate is -0.07.
How many shares outstanding does Biodesix have?
Biodesix has 146,633,350 shares outstanding.
What happened to Biodesix’s price movement after its last earnings report?
Biodesix reported an EPS of -$0.08 in its last earnings report, missing expectations of -$0.069. Following the earnings report the stock price went down -11.111%.
Which hedge fund is a major shareholder of Biodesix?
Currently, no hedge funds are holding shares in BDSX
Biodesix Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1.75 (272.34% Upside)
$1.75 (272.34% Upside)
Blogger Sentiment
Bullish
BDSX Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.3%
Last 30 Days ▼ 10.3%
Last 30 Days ▼ 10.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.89%
12-Months-Change
Fundamentals
Return on Equity
-219.68%
Trailing 12-Months
Asset Growth
-24.26%
Trailing 12-Months
Company Description
Biodesix
Biodesix, Inc. (BDSX) is a leading biotechnology company specializing in the development and commercialization of blood-based diagnostic solutions. Focused primarily on the oncology sector, the company offers a suite of diagnostic tests that help clinicians make more informed decisions about patient care. These tests are designed to improve outcomes for patients with lung cancer by providing insights into the disease's progression and response to treatment.
BDSX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects positive developments in revenue growth, particularly in lung diagnostic testing and development services, as well as in operational efficiency with improved gross margins. However, these positives are offset by increased operating expenses, net loss, and adjusted EBITDA loss, which paint a balanced picture of achievements and challenges.View all BDSX earnings summariesBDSX Stock 12 Month Forecast
Average Price Target
$1.75
▲(272.34% Upside)
Technical Analysis
Ownership Overview
52.59% Insiders
3.16% Mutual Funds
14.83% Other Institutional Investors
27.22% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---